Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

Stopped Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt to be clinically relevant.

Conditions

• Non Small Cell Lung Cancer
• Advanced Lung Non-Small Cell Carcinoma
• PD-L1 Gene Mutation

Interventions

• DRUG: Pembrolizumab
• DRUG: Pemetrexed
• DRUG: Paclitaxel
• DRUG: Nab-paclitaxel
• OTHER: Laboratory Biomarker Analysis

Sponsor

Shirish Gadgeel

Collaborators

• [object Object]